当前蛋白身份:P50613 重新检索
本组结构的主要差异维度
构建体不同 突变/修饰不同 组装状态不同 配体/离子不同 实验方法不同 实验环境不同 结构质量指标不同

差异标签只比较当前检索结果;所有PDB和assembly原始记录仍分别保留。

相关结构差异明细

一行代表一个 PDB 条目中的一个 biological assembly;同一蛋白的多个单体会分别列出。

PDB 条目 Assembly / 聚集状态 构建体 突变与修饰 配体、离子与非聚合物 实验方法 实验环境 结构质量
1UA2 Crystal Structure of Human CDK7 提交 2004-08-11 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 1–346(346 aa)
非标准单体:是(mmCIF未提供具体位点) ATP ADENOSINE-5'-TRIPHOSPHATE × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 6.4;277 K;Na Citrate, Na Acetate, PEG 4000, glycerol, NDSB201, ATP, pH 6.4, VAPOR DIFFUSION, SITTING DROP, temperature 4.0K
分辨率 3.02 Å R-free 0.288
1UA2 Crystal Structure of Human CDK7 提交 2004-08-11 Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 B 1–346(346 aa)
非标准单体:是(mmCIF未提供具体位点) ATP ADENOSINE-5'-TRIPHOSPHATE × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 6.4;277 K;Na Citrate, Na Acetate, PEG 4000, glycerol, NDSB201, ATP, pH 6.4, VAPOR DIFFUSION, SITTING DROP, temperature 4.0K
分辨率 3.02 Å R-free 0.288
1UA2 Crystal Structure of Human CDK7 提交 2004-08-11 Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 C 1–346(346 aa)
非标准单体:是(mmCIF未提供具体位点) ATP ADENOSINE-5'-TRIPHOSPHATE × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 6.4;277 K;Na Citrate, Na Acetate, PEG 4000, glycerol, NDSB201, ATP, pH 6.4, VAPOR DIFFUSION, SITTING DROP, temperature 4.0K
分辨率 3.02 Å R-free 0.288
1UA2 Crystal Structure of Human CDK7 提交 2004-08-11 Assembly 4 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 D 1–346(346 aa)
非标准单体:是(mmCIF未提供具体位点) ATP ADENOSINE-5'-TRIPHOSPHATE × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 6.4;277 K;Na Citrate, Na Acetate, PEG 4000, glycerol, NDSB201, ATP, pH 6.4, VAPOR DIFFUSION, SITTING DROP, temperature 4.0K
分辨率 3.02 Å R-free 0.288
6O9L Human holo-PIC in the closed state 提交 2019-03-14 Assembly 1 蛋白–DNA 异源复合物;蛋白 × 31 PDB 声明:33-meric(33) 与全部聚合物一致
链 8 1–346(346 aa)
未记录 MG MAGNESIUM ION × 2 ZN ZINC ION × 17 SF4 IRON/SULFUR CLUSTER × 1 ELECTRON MICROSCOPY
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 7.20 Å
6XBZ Structure of the human CDK-activating kinase 提交 2020-06-07 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 J 1–346(346 aa)
非标准单体:是(mmCIF未提供具体位点) MG MAGNESIUM ION × 1 AGS PHOSPHOTHIOPHOSPHORIC ACID-ADENYLATE ESTER × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.9
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 2.80 Å
6XD3 Structure of the human CAK in complex with THZ1 提交 2020-06-09 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 J 1–346(346 aa)
非标准单体:是(mmCIF未提供具体位点) V0G N-(3-{[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)-4-{[4-(dimethylamino)butanoyl]amino}benzamide × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.9
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 3.30 Å
7B5O Cryo-EM structure of the human CAK bound to ICEC0942 at 2.5 Angstroms resolution 提交 2020-12-05 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 J 1–346(346 aa)
未记录 I74 (3R,4R)-4-[[[7-[(phenylmethyl)amino]-3-propan-2-yl-pyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]piperidin-3-ol × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.9
cryo-EM玻璃化条件 冷冻剂 ETHANE-PROPANE
分辨率 2.50 Å
7B5Q Cryo-EM structure of the human CAK bound to ICEC0942 (PHENIX-OPLS3e) 提交 2020-12-05 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 J 1–346(346 aa)
未记录 I74 (3R,4R)-4-[[[7-[(phenylmethyl)amino]-3-propan-2-yl-pyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]piperidin-3-ol × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.9
cryo-EM玻璃化条件 冷冻剂 ETHANE-PROPANE
分辨率 2.50 Å
7EGB TFIID-based holo PIC on SCP promoter 提交 2021-03-24 Assembly 1 蛋白–DNA 异源复合物;蛋白 × 49 PDB 声明:51-meric(51) 与全部聚合物一致
链 8 1–346(346 aa)
未记录 ZN ZINC ION × 17 SF4 IRON/SULFUR CLUSTER × 1 MG MAGNESIUM ION × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.9
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 3.30 Å
7EGC p53-bound TFIID-based holo PIC on HDM2 promoter 提交 2021-03-24 Assembly 1 蛋白–DNA 异源复合物;蛋白 × 49 PDB 声明:51-meric(51) 与全部聚合物一致
链 8 1–346(346 aa)
未记录 ZN ZINC ION × 16 SF4 IRON/SULFUR CLUSTER × 1 MG MAGNESIUM ION × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.9
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 3.90 Å
7ENA TFIID-based PIC-Mediator holo-complex in pre-assembled state (pre-hPIC-MED) 提交 2021-04-16 Assembly 1 蛋白–DNA 异源复合物;蛋白 × 74 PDB 声明:76-meric(76) 与全部聚合物一致
链 8 1–346(346 aa)
未记录 ZN ZINC ION × 16 MG MAGNESIUM ION × 1 SF4 IRON/SULFUR CLUSTER × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.9
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 4.07 Å
7ENC TFIID-based PIC-Mediator holo-complex in fully-assembled state (hPIC-MED) 提交 2021-04-16 Assembly 1 蛋白–DNA 异源复合物;蛋白 × 74 PDB 声明:76-meric(76) 与全部聚合物一致
链 8 1–346(346 aa)
未记录 ZN ZINC ION × 16 SF4 IRON/SULFUR CLUSTER × 1 MG MAGNESIUM ION × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.9
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 4.13 Å
7LBM Structure of the human Mediator-bound transcription pre-initiation complex 提交 2021-01-08 Assembly 1 蛋白–DNA 异源复合物;蛋白 × 54 PDB 声明:56-meric(56) 与全部聚合物一致
链 e 1–346(346 aa)
未记录 MG MAGNESIUM ION × 2 ZN ZINC ION × 16 SF4 IRON/SULFUR CLUSTER × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.9
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 4.80 Å
7NVR Human Mediator with RNA Polymerase II Pre-initiation complex 提交 2021-03-15 Assembly 1 蛋白–DNA 异源复合物;蛋白 × 56 PDB 声明:58-meric(58) 与全部聚合物一致
链 8 1–346(346 aa)
未记录 SF4 IRON/SULFUR CLUSTER × 1 ZN ZINC ION × 18 MG MAGNESIUM ION × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.5
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 4.50 Å
8BVW RNA polymerase II pre-initiation complex with the distal +1 nucleosome (PIC-Nuc18W) 提交 2022-12-20 Assembly 1 蛋白–DNA 异源复合物;蛋白 × 40 PDB 声明:42-meric(42) 与全部聚合物一致
链 8 1–346(346 aa)
突变:0 SF4 IRON/SULFUR CLUSTER × 1 ZN ZINC ION × 17 MG MAGNESIUM ION × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.5
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 4.00 Å
8BYQ RNA polymerase II pre-initiation complex with the proximal +1 nucleosome (PIC-Nuc10W) 提交 2022-12-14 Assembly 1 蛋白–DNA 异源复合物;蛋白 × 38 PDB 声明:40-meric(40) 与全部聚合物一致
链 8 1–346(346 aa)
未记录 SF4 IRON/SULFUR CLUSTER × 1 ZN ZINC ION × 16 MG MAGNESIUM ION × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.5
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 4.10 Å
8GXQ PIC-Mediator in complex with +1 nucleosome (T40N) in MH-binding state 提交 2022-09-21 Assembly 1 蛋白–DNA 异源复合物;蛋白 × 83 PDB 声明:87-meric(87) 与全部聚合物一致
链 HI 1–346(346 aa)
突变:K41A ZN ZINC ION × 19 SF4 IRON/SULFUR CLUSTER × 1 MG MAGNESIUM ION × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.9
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 5.04 Å
8GXS PIC-Mediator in complex with +1 nucleosome (T40N) in H-binding state 提交 2022-09-21 Assembly 1 蛋白–DNA 异源复合物;蛋白 × 83 PDB 声明:87-meric(87) 与全部聚合物一致
链 HI 1–346(346 aa)
突变:K41A ZN ZINC ION × 19 SF4 IRON/SULFUR CLUSTER × 1 MG MAGNESIUM ION × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.9
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 4.16 Å
8ORM Cryo-EM structure of CAK-THZ1 提交 2023-04-14 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 J 1–346(346 aa)
未记录 V0G N-(3-{[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)-4-{[4-(dimethylamino)butanoyl]amino}benzamide × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.9
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 1.90 Å
8P4Z Crystal structure of the human CDK7 kinase domain in complex with LDC4297 提交 2023-05-23 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 10–311(302 aa)
未记录 WZ8 2-[(3R)-piperidin-3-yl]oxy-8-propan-2-yl-N-[(2-pyrazol-1-ylphenyl)methyl]pyrazolo[1,5-a][1,3,5]triazin-4-amine × 1 GOL GLYCEROL × 2 PGE TRIETHYLENE GLYCOL × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;0.2 M ammonium acetate, 0.1 M sodium citrate, 12% w/v PEG 3350, 0.2 M NDSB-201
分辨率 2.75 Å R-free 0.251
8P4Z Crystal structure of the human CDK7 kinase domain in complex with LDC4297 提交 2023-05-23 Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 B 10–311(302 aa)
未记录 WZ8 2-[(3R)-piperidin-3-yl]oxy-8-propan-2-yl-N-[(2-pyrazol-1-ylphenyl)methyl]pyrazolo[1,5-a][1,3,5]triazin-4-amine × 1 GOL GLYCEROL × 6 1PE PENTAETHYLENE GLYCOL × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;0.2 M ammonium acetate, 0.1 M sodium citrate, 12% w/v PEG 3350, 0.2 M NDSB-201
分辨率 2.75 Å R-free 0.251
8P6V Cryo-EM structure of CAK in complex with inhibitor ICEC0942 提交 2023-05-30 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 J 1–346(346 aa)
未记录 I74 (3R,4R)-4-[[[7-[(phenylmethyl)amino]-3-propan-2-yl-pyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]piperidin-3-ol × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.9
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 1.90 Å
8P6W Cryo-EM structure of CAK in complex with inhibitor BS-181 提交 2023-05-30 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 J 1–346(346 aa)
未记录 X2H ~{N}5-(6-azanylhexyl)-~{N}7-(phenylmethyl)-3-propan-2-yl-pyrazolo[1,5-a]pyrimidine-5,7-diamine × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.9
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 1.90 Å
8P6X Cryo-EM structure of CAK in complex with inhibitor BS-194 提交 2023-05-30 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 J 1–346(346 aa)
未记录 NS9 (2S,3S)-3-{[7-(benzylamino)-3-(1-methylethyl)pyrazolo[1,5-a]pyrimidin-5-yl]amino}butane-1,2,4-triol × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.9
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 1.90 Å
8P6Y Cryo-EM structure of CAK in complex with nucleotide analogue ATPgS 提交 2023-05-30 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 J 1–346(346 aa)
未记录 AGS PHOSPHOTHIOPHOSPHORIC ACID-ADENYLATE ESTER × 1 MG MAGNESIUM ION × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.9
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 1.90 Å
8P6Z Cryo-EM structure of CAK in complex with inhibitor ICEC0510-R 提交 2023-05-30 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 J 1–346(346 aa)
未记录 X4L N7-(phenylmethyl)-3-propan-2-yl-N5-[(3R)-pyrrolidin-3-yl]pyrazolo[1,5-a]pyrimidine-5,7-diamine × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.9
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 2.10 Å
8P70 Cryo-EM structure of CAK in complex with inhibitor ICEC0510-S 提交 2023-05-30 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 J 1–346(346 aa)
未记录 X4Q N7-(phenylmethyl)-3-propan-2-yl-N5-[(3S)-pyrrolidin-3-yl]pyrazolo[1,5-a]pyrimidine-5,7-diamine × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.9
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 2.00 Å
8P71 Cryo-EM structure of CAK in complex with inhibitor ICEC0574 提交 2023-05-30 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 J 1–346(346 aa)
未记录 X4F (3R,4S)-4-[[7-[(phenylmethyl)amino]-3-propan-2-yl-pyrazolo[1,5-a]pyrimidin-5-yl]amino]pyrrolidin-3-ol × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.9
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 2.00 Å
8P72 Cryo-EM structure of CAK in complex with inhibitor ICEC0768 提交 2023-05-30 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 J 1–346(346 aa)
未记录 X2Z ~{N}7-(phenylmethyl)-~{N}5-[(3~{S})-piperidin-3-yl]-3-propan-2-yl-pyrazolo[1,5-a]pyrimidine-5,7-diamine × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.9
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 1.90 Å
8P73 Cryo-EM structure of CAK in complex with inhibitor ICEC0829 提交 2023-05-30 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 J 1–346(346 aa)
未记录 X50 (3R,4R)-4-[[[7-[(phenylmethyl)amino]-3-propan-2-yl-pyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]piperidine-3,4-diol × 1 X58 (3S,4S)-4-[[[7-[(phenylmethyl)amino]-3-propan-2-yl-pyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]piperidine-3,4-diol × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.9
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 2.00 Å
8P74 Cryo-EM structure of CAK in complex with inhibitor ICEC0880 (ring-up conformation) 提交 2023-05-30 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 J 1–346(346 aa)
未记录 X3Z (2S,3S)-3-[[7-[(2-bromophenyl)methylamino]-3-propan-2-yl-pyrazolo[1,5-a]pyrimidin-5-yl]amino]butane-1,2,4-triol × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.9
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 2.20 Å
8P75 Cryo-EM structure of CAK in complex with inhibitor ICEC0880 (ring-down conformation) 提交 2023-05-30 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 J 1–346(346 aa)
未记录 X3Z (2S,3S)-3-[[7-[(2-bromophenyl)methylamino]-3-propan-2-yl-pyrazolo[1,5-a]pyrimidin-5-yl]amino]butane-1,2,4-triol × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.9
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 2.00 Å
8P76 Cryo-EM structure of CAK in complex with inhibitor ICEC0914 提交 2023-05-30 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 J 1–346(346 aa)
未记录 X1W N5-[(3S,4R)-4-phenylmethoxypyrrolidin-3-yl]-N7-(phenylmethyl)-3-propan-2-yl-pyrazolo[1,5-a]pyrimidine-5,7-diamine × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.9
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 2.00 Å
8P77 Cryo-EM structure of CAK in complex with inhibitor ICEC0943 提交 2023-05-30 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 J 1–346(346 aa)
未记录 I73 (3S,4S)-4-[[[7-[(phenylmethyl)amino]-3-propan-2-yl-pyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]piperidin-3-ol × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.9
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 1.80 Å
8P78 Cryo-EM structure of CAK in complex with inhibitor dinaciclib 提交 2023-05-30 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 J 1–346(346 aa)
未记录 1QK 3-[({3-ethyl-5-[(2S)-2-(2-hydroxyethyl)piperidin-1-yl]pyrazolo[1,5-a]pyrimidin-7-yl}amino)methyl]-1-hydroxypyridinium × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.9
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 1.90 Å
8P79 Cryo-EM structure of CAK with averaged inhibitor density 提交 2023-05-30 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 J 1–346(346 aa)
未记录 未记录非水小分子 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.9;Structure obtained by combining data from six samples of CAK bound to different non-covalent inhibitors. Four samples contained 5 mM beta-mercaptoethanol and two samples did not.
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 1.70 Å
8P7L Cryo-EM structure of CDK7 subunit of CAK in complex with inhibitor LDC4297 提交 2023-05-30 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 J 1–346(346 aa)
未记录 WD9 2-[(3S)-piperidin-3-yl]oxy-8-propan-2-yl-N-[(2-pyrazol-1-ylphenyl)methyl]pyrazolo[1,5-a][1,3,5]triazin-4-amine × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.9
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 2.10 Å
8PLZ Cryo-EM structure of CAK in complex with inhibitor CT7030 提交 2023-06-27 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 J 1–346(346 aa)
未记录 ZQ6 (3~{R},4~{R})-4-[[[7-[(2-methoxyphenyl)methylamino]-3-propan-2-yl-pyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]piperidin-3-ol × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.9
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 1.90 Å
8PYR Crystal structure of the dual T-loop phosphorylated Cdk7/CycH/Mat1 complex 提交 2023-07-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 1–346(346 aa)
非标准单体:是(mmCIF未提供具体位点) EDO 1,2-ETHANEDIOL × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;288 K;0.1 M Hepes (pH 7.0), 12% (v/w) medium weight PEG mix of PEG6K and PEG4K, 10% ethylene-glycol, and 0.2 M NDSB
分辨率 2.15 Å R-free 0.241
8PYR Crystal structure of the dual T-loop phosphorylated Cdk7/CycH/Mat1 complex 提交 2023-07-26 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 E 1–346(346 aa)
非标准单体:是(mmCIF未提供具体位点) EDO 1,2-ETHANEDIOL × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 7;288 K;0.1 M Hepes (pH 7.0), 12% (v/w) medium weight PEG mix of PEG6K and PEG4K, 10% ethylene-glycol, and 0.2 M NDSB
分辨率 2.15 Å R-free 0.241
8R99 A soakable crystal form of human CDK7 in complex with AMP-PNP 提交 2023-11-30 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 1–346(346 aa)
突变:W132R, S164D, T170E ANP PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER × 1 MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;277 K;.1M (NH4)3 citrate .2M NDSB-201 15.2% PEG 3350
分辨率 1.81 Å R-free 0.220
8R9A A soakable crystal form of human CDK7 in complex with AMP-PNP 提交 2023-11-30 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 1–346(346 aa)
突变:W132R,S164D, T170E PEG DI(HYDROXYETHYL)ETHER × 1 I74 (3R,4R)-4-[[[7-[(phenylmethyl)amino]-3-propan-2-yl-pyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]piperidin-3-ol × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;277 K;.2M Na2HPO4 20% PEG 3350
分辨率 1.71 Å R-free 0.294
8R9B A soakable crystal form of human CDK7 in complex with AMP-PNP 提交 2023-11-30 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 1–326(326 aa)
突变:S164D, T170E, del327-346 ANP PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER × 1 MG MAGNESIUM ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 5.6;277 K;19% 2-propanol, 5% glycerol, 19%PEG4K, 0.095M Na3citrate pH5.6/HCl
分辨率 2.21 Å R-free 0.243
8R9B A soakable crystal form of human CDK7 in complex with AMP-PNP 提交 2023-11-30 Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 B 1–326(326 aa)
突变:S164D, T170E, del327-346 ANP PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER × 1 MG MAGNESIUM ION × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 5.6;277 K;19% 2-propanol, 5% glycerol, 19%PEG4K, 0.095M Na3citrate pH5.6/HCl
分辨率 2.21 Å R-free 0.243
8R9B A soakable crystal form of human CDK7 in complex with AMP-PNP 提交 2023-11-30 Assembly 3 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 C 1–326(326 aa)
突变:S164D, T170E, del327-346 ANP PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 5.6;277 K;19% 2-propanol, 5% glycerol, 19%PEG4K, 0.095M Na3citrate pH5.6/HCl
分辨率 2.21 Å R-free 0.243
8R9B A soakable crystal form of human CDK7 in complex with AMP-PNP 提交 2023-11-30 Assembly 4 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 D 1–326(326 aa)
突变:S164D, T170E, del327-346 ANP PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER × 1 MG MAGNESIUM ION × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 5.6;277 K;19% 2-propanol, 5% glycerol, 19%PEG4K, 0.095M Na3citrate pH5.6/HCl
分辨率 2.21 Å R-free 0.243
8R9O A soakable crystal form of human CDK7 in complex with AMP-PNP 提交 2023-11-30 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 1–346(346 aa)
突变:W132R,S164D, T170E YN3 ~{N}-[(1~{S})-2-(dimethylamino)-1-phenyl-ethyl]-6,6-dimethyl-3-[[4-(propanoylamino)phenyl]carbonylamino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;277 K;0.1M (NH4)3 citrate 15% PEG 3350
分辨率 2.22 Å R-free 0.344
8R9O A soakable crystal form of human CDK7 in complex with AMP-PNP 提交 2023-11-30 Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 B 1–346(346 aa)
突变:W132R,S164D, T170E YN3 ~{N}-[(1~{S})-2-(dimethylamino)-1-phenyl-ethyl]-6,6-dimethyl-3-[[4-(propanoylamino)phenyl]carbonylamino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;277 K;0.1M (NH4)3 citrate 15% PEG 3350
分辨率 2.22 Å R-free 0.344
8R9S A soakable crystal form of human CDK7 in complex with AMP-PNP 提交 2023-11-30 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 1–346(346 aa)
突变:W132R,S164D, T170E PE3 3,6,9,12,15,18,21,24,27,30,33,36,39-TRIDECAOXAHENTETRACONTANE-1,41-DIOL × 2 PEG DI(HYDROXYETHYL)ETHER × 1 YPK [(3S)-1-[4-(dimethylamino)butanoyl]pyrrolidin-3-yl] 4-[(5-methyl-3-propan-2-yl-pyrazolo[1,5-a]pyrimidin-7-yl)amino]piperidine-1-carboxylate × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;277 K;20% Glycerol .02M KNa tartrate .02M NH4 acetate .02M Na formate .02M Na oxamate .02M Na3 citrate 10% PEG 4000 .1M pH=7.5 MOPS/NaHEPES
分辨率 2.78 Å R-free 0.296
8R9S A soakable crystal form of human CDK7 in complex with AMP-PNP 提交 2023-11-30 Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 B 1–346(346 aa)
突变:W132R,S164D, T170E PE3 3,6,9,12,15,18,21,24,27,30,33,36,39-TRIDECAOXAHENTETRACONTANE-1,41-DIOL × 2 YPK [(3S)-1-[4-(dimethylamino)butanoyl]pyrrolidin-3-yl] 4-[(5-methyl-3-propan-2-yl-pyrazolo[1,5-a]pyrimidin-7-yl)amino]piperidine-1-carboxylate × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;277 K;20% Glycerol .02M KNa tartrate .02M NH4 acetate .02M Na formate .02M Na oxamate .02M Na3 citrate 10% PEG 4000 .1M pH=7.5 MOPS/NaHEPES
分辨率 2.78 Å R-free 0.296
8R9U A soakable crystal form of human CDK7 in complex with AMP-PNP 提交 2023-11-30 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 1–346(346 aa)
突变:W132R,S164D, T170E YNK 7-dimethylphosphoryl-3-[2-[[(3~{S})-6,6-dimethylpiperidin-3-yl]amino]-5-(trifluoromethyl)pyrimidin-4-yl]-1~{H}-indole-6-carbonitrile × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;277 K;0.1M (NH4)3 citrate 15% PEG 3350
分辨率 1.94 Å R-free 0.340
8R9U A soakable crystal form of human CDK7 in complex with AMP-PNP 提交 2023-11-30 Assembly 2 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 B 1–346(346 aa)
突变:W132R,S164D, T170E YNK 7-dimethylphosphoryl-3-[2-[[(3~{S})-6,6-dimethylpiperidin-3-yl]amino]-5-(trifluoromethyl)pyrimidin-4-yl]-1~{H}-indole-6-carbonitrile × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;277 K;0.1M (NH4)3 citrate 15% PEG 3350
分辨率 1.94 Å R-free 0.340
8S0R Cryo-EM structure of CAK modified by covalent inhibitor SY-1365 提交 2024-02-14 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 J 1–346(346 aa)
未记录 A1H46 ~{N}-[(1~{S},3~{R})-3-[[5-chloranyl-4-(1~{H}-indol-3-yl)pyrimidin-2-yl]amino]-1-methyl-cyclohexyl]-5-[4-(dimethylamino)butanoylamino]pyridine-2-carboxamide × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.9
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 2.40 Å
8S0T Cryo-EM structure of CAK in complex with SY-5609 提交 2024-02-14 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 J 1–346(346 aa)
未记录 YNK 7-dimethylphosphoryl-3-[2-[[(3~{S})-6,6-dimethylpiperidin-3-yl]amino]-5-(trifluoromethyl)pyrimidin-4-yl]-1~{H}-indole-6-carbonitrile × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.9;Buffer contained 54 uM inhibitor SY-5609.
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 2.30 Å
9HIX Cryo-EM structure of CAK (CDK7 D97N mutant) in complex with THZ1 提交 2024-11-27 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 J 1–346(346 aa)
未记录 V0G N-(3-{[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)-4-{[4-(dimethylamino)butanoyl]amino}benzamide × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.9
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 2.60 Å
9HIY Cryo-EM structure of CAK (CDK7 D97N mutant) in complex with ATPgS 提交 2024-11-27 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 J 1–346(346 aa)
未记录 AGS PHOSPHOTHIOPHOSPHORIC ACID-ADENYLATE ESTER × 1 MG MAGNESIUM ION × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.9
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 2.30 Å
9HJ0 Cryo-EM structure of CAK (CDK7 D97N mutant) in complex with Samuraciclib 提交 2024-11-27 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 J 1–346(346 aa)
未记录 I74 (3R,4R)-4-[[[7-[(phenylmethyl)amino]-3-propan-2-yl-pyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]piperidin-3-ol × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.9
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 2.60 Å
9I9I Cryo-EM structure of CAK-CDK11 提交 2025-02-06 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 J 1–346(346 aa)
未记录 ADP ADENOSINE-5'-DIPHOSPHATE × 2 MG MAGNESIUM ION × 2 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.9
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 3.50 Å
9I9J Cryo-EM structure of CAK-CDK2 (determined in the presence of ADP-nitrate) 提交 2025-02-06 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 J 1–346(346 aa)
未记录 ADP ADENOSINE-5'-DIPHOSPHATE × 2 MG MAGNESIUM ION × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.5
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 3.10 Å
9I9K Cryo-EM structure of CAK-CDK2 (determined in the presence of ADP-AlFx) 提交 2025-02-06 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 J 1–346(346 aa)
未记录 ADP ADENOSINE-5'-DIPHOSPHATE × 2 MG MAGNESIUM ION × 4 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.5
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 2.40 Å
9QCV Cryo-EM structure of CAK-CDK2-cyclin A2 bound to AMP-PNP 提交 2025-03-05 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 5 PDB 声明:pentameric(5) 与蛋白数一致
链 J 1–346(346 aa)
未记录 ANP PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER × 2 MG MAGNESIUM ION × 2 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.5
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 2.50 Å
9QCX Cryo-EM structure of apo-CAK-CDK2-cyclin A2 提交 2025-03-05 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 5 PDB 声明:pentameric(5) 与蛋白数一致
链 J 1–346(346 aa)
未记录 未记录非水小分子 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.5
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 2.60 Å
9QJN Cryo-EM structure of the human CAK bound to OTS964 提交 2025-03-19 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 J 1–346(346 aa)
未记录 NK3 OTS964 × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.9
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 2.40 Å
9SKQ Cryo-EM structure of CAK-CDK1-cyclin B1 提交 2025-09-02 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 5 PDB 声明:pentameric(5) 与蛋白数一致
链 J 1–346(346 aa)
未记录 ANP PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER × 2 MG MAGNESIUM ION × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.5
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 3.40 Å